MetAlert (OTC: MLRT), a pioneer in location-sensitive, health-monitoring devices and wearable technology products for remote patient monitoring, spotlighted in a recent Q&A analyst report released by Ludlow Research. In the article, MLRT representations respond to questions, providing an overview of the company and discussing specific topics investors and shareholders might be interested in. The report delved into the company’s recent restructuring, name change and ticker symbol change, with the company stating that “we waited patiently to do this until we had a clean balance sheet and were prepared to take the company to the next level.” The report noted that the company recognized a tremendous opportunity, but the previous name, stock price and market cap didn’t reflect the company’s vision, mission and direction. The report also touched on supply chain issues, order fulfillment, a potential uplisting and becoming a reseller of RoomMate, a remote monitoring device to track people at home or assisted-living facilities. The company also responded to concerns about how a possible recession might impact the company. “We don’t burn a lot of cash,” the company stated in the analyst brief. “Besides keeping our expenses to a minimum, not spending money on lavish things, our main counter measure is thanks to our board and management team, which take much lower than industry standard wages, they also defer approximately a third of their cash compensation. If you look at our balance sheet, just about all our debt, is years of deferred cash comp. Talk about keeping management motivated, we all know we need to work very hard in order to eventually get paid. Between not spending a lot, not subordinating a heavy debt load, along with providing high margin must have products and services, is how we plan to face a possible economic slowdown. Remember our products are not luxury items that people turn off when the economy slows down, our products are essential to our users, their loved ones, and caregivers.”

To view the full article, visit https://ibn.fm/W9yoy

About MetAlert Inc.

MetAlert, a pioneer in smart, mobile, and wearable tracking and recovery location-based solutions, is supported through a proprietary IoT enterprise monitoring platform and intellectual property portfolio. The company offers a global end-to-end solution of hardware, software and connectivity and develops two-way GPS tracking technologies, which seamlessly integrate with consumer products and enterprise applications. Utilizing the latest in miniaturized, low-power consumption GPS, cellular, RF, NFC and BLE technology, MetAlert products enable subscribers to track in real time the whereabouts of people or high-value assets. Known for its game-changing and award-winning patented GPS SmartSole — think Dr. Scholl’s meets LoJack — the world’s first invisible, wearable, technology-tracking device created for those at risk of wandering due to Alzheimer’s, dementia, autism or traumatic brain injury. MetAlert’s business model is built around technology innovation, and the company holds dozens of patents, with many issued patents in the area of GPS tracking. MetAlert has international distributors servicing customers across the globe with subscribers in more than 40 countries; MetAlert is also a U.S. military government contractor. Other customers include public health authorities and municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes and consumers. For more information about this company, please visit www.MetAlert.com

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.